| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 3 data readout example | SGT-610 (hedgehog signaling pathway blocker) Prevention of basal cell carcinomas in Gorlin syndrome patients | Phase 3 | — | Subscribe to access the data. | Biologics | Oncology | |
phase 3 data readout example | SGT-610 (hedgehog signaling pathway blocker) Prevention of basal cell carcinomas in Gorlin syndrome patients | Phase 3 | — | Subscribe to access the data. | Biologics | Oncology | |
phase 3 data readout example | SGT-610 (hedgehog signaling pathway blocker) Prevention of basal cell carcinomas in Gorlin syndrome patients | Phase 3 | — | Subscribe to access the data. | Biologics | Oncology |
Recent Updates
Recently added Catalysts
Sol-Gel Technologies Ltd.$73.95
-2.41 (-3.16%)
D 37Pipeline Score Overvalued Pharma · Clinical
Market Cap
250.83 M
EPS
-2.20
P/E Ratio
-
Value Trade
2.00 M
11.66 %
Week
2.29 %
1 Month
-2.33 %
3 Month
104.67 %
6 Month
-24.77 %
5 Year
-49.95 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
54.15 K
52 Week Range
6.80 - 97.97
% held by Insiders
59.82 %
% held by Institutions
41.11 %
Enterprise Value
227.82 M
Total Shares
2.81 M
Short %
4 %
Float Shares
1.06 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Sol-Gel Technologies Ltd.
342Total events
8Upcoming
109Tier-1 (high impact)
2017 – 2027Coverage
Upcoming catalysts 8
Event history 334
May 2026
▲Patent GrantedSGT-610IP / Competition
Notice of Allowance for method-of-use patent for topical patidegib (SGT-610) extending IP protection to 2044
Gorlin syndromesource ↗
Apr 2026
▲Partnership / LicenseTwyneoApprovedCorporate
Exclusive license agreement with Sun Pharmaceutical Industries Ltd. for commercialization of TWYNEO in India
Q2 2026
◆Topline ReadoutSGT-610Clinical Data
Top-line results for SGT-610 expected in Q2 2026
Gorlin Syndromesource ↗
Mar 23, 2026
▼Equity OfferingCorporate
Pricing of oversubscribed underwritten offering of 459,112 shares at $72.00 per share for gross proceeds of $33.1 million
Mar 19, 2026
●Quarterly UpdateCorporate
Filed annual report on Form 20-F for fiscal year ended December 31, 2025
Mar 2026
▼Equity OfferingCorporate
Oversubscribed underwritten offering raising ~$33.1 million gross proceeds
2026
▲Product LaunchEPSOLAYApprovedPost-Market
EPSOLAY expected to launch in majority of new territories in 2026
Dec 17, 2025
▼Topline ReadoutSGT-210Clinical Data
Unblinding of Phase 1b proof-of-concept study of SGT-210 in Darier disease
Darier diseasesource ↗
Dec 17, 2025
▼Program DiscontinuationSGT-210Corporate
Decision not to advance SGT-210 to next stage of development in Darier disease
Darier diseasesource ↗
Drug Pipeline Intelligence
D37
Pipeline Score $159M
Pipeline ValueOvervalued
Valuation Signal6
Drugs Scored0.6x
rNPV / MCap Top 51%
Micro Cap (rank 447 of 911)
Percentile RankSol-Gel Technologies Ltd. faces pipeline headwinds (37/100), with $1.0B risk-adjusted pipeline value, led by S6G5T-3 in Acne Vulgaris (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S6G5T-3 Small molecule | Acne Vulgaris | Phase 3 | NCT04059523 | 58% | $294M | COMPLETED | 1,646 | - | - | Feb 6, 2020 | - | Mar 18, 2020 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
SGT-210 | Darier disease | Phase 1b | 2025-12-17 | did not show differentiation between SGT-210 and vehicle | Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease Read More | |
SGT-210 | Darier disease | Phase 1b | 2025-12-17 | did not show differentiation between SGT-210 and vehicle | Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease Read More | |
SGT-210 | Darier disease | Phase 1b | 2025-12-17 | did not show differentiation between SGT-210 and vehicle | Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SLGL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SLGL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SLGLSol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Sol-Gel Technologies reported its Q1 2026 financial results, highlighting significant corporate advancements. The company received a Notice of Allowance for a method-of-use patent for SGT-610, extending protection until 2044. Additionally, an oversubscribed offering raised $33.1 million, while the pivotal Phase 3 trial for Gorlin syndrome is on track for results in Q4 2026. Sol-Gel also signed a licensing agreement with Sun Pharma for TWYNEO® in India.
Read more →SLGL▲ +20.9%on this news
Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering
Sol-Gel Technologies Ltd. has announced the pricing of an oversubscribed underwritten offering of 459,112 ordinary shares at $72.00 per share, aiming to raise approximately $33.1 million. The proceeds will support the development of SGT-610, a Phase 3 treatment for Gorlin syndrome, alongside general corporate purposes. The offering is expected to close on March 25, 2026.
Read more →SLGL▲ +8.5%on this newsshared move
Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025
Sol-Gel Technologies, Ltd. has filed its annual report on Form 20-F with the SEC for the fiscal year ending December 31, 2025. This report includes audited financial statements and is available for shareholders and the public online. The company is advancing its investigational drug SGT-610, a topical treatment for preventing basal cell carcinoma lesions, alongside its existing FDA-approved products. The filing underscores Sol-Gel's commitment to transparency and innovation in dermatological treatments.
Read more →SLGLSol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease
Sol-Gel Technologies announced that the unblinded data from its Phase 1b study of SGT-210 for Darier disease did not demonstrate efficacy compared to the vehicle control. As a result, the company has decided not to proceed with further development of SGT-210. Instead, Sol-Gel will focus on small feasibility studies in other areas and continue its Phase 3 program for SGT-610 in Gorlin syndrome.
Read more →SLGLSol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Sol-Gel Technologies reported its Q3 2025 financial results, highlighting ongoing progress in its late-stage pipeline, particularly the pivotal Phase 3 trial of SGT-610 for Gorlin syndrome. The company noted a significant decrease in total revenue compared to the previous year, alongside a net loss of $5.9 million. However, the approval of EPSOLAY in Canada and new partnerships are expected to enhance revenue streams moving forward.
Read more →SLGL▲ +19.7%on this news
Sol-Gel Announces Health Canada Approval of EPSOLAY®
Sol-Gel Technologies announced that Health Canada has approved EPSOLAY for treating inflammatory lesions of rosacea in adults. This approval follows a partnership with Searchlight Pharma, which will commercialize EPSOLAY in Canada. Sol-Gel stands to gain up to $11 million in milestone payments and royalties, bolstering its financial strategy and growth potential.
Read more →SLGLSol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Sol-Gel Technologies reported strong financial results for Q2 2025, with revenues increasing significantly compared to the previous year. The company completed enrollment in its Phase 3 trial for SGT-610, aimed at treating Gorlin syndrome, and anticipates reporting data in late 2026. Despite some recruitment challenges for another product, the company is optimistic about future revenues from both existing products and international markets.
Read more →SLGLSol-Gel Reports First Quarter 2025 Results
Sol-Gel Technologies, Ltd. reported its financial results for Q1 2025, showing a revenue increase to $1 million. However, the company experienced a net loss of $8.8 million, up from $6.3 million in Q1 2024. R&D expenses rose significantly, primarily due to costs associated with manufacturing development for future products. Despite these challenges, Sol-Gel has enough cash to fund operations into 2027.
Read more →SLGLSol-Gel Announces Reverse Share Split
Sol-Gel Technologies Ltd. has announced a 10-for-1 reverse share split to increase its share price and comply with Nasdaq's minimum bid price requirement. Shareholders approved the split during a special meeting, and it will take effect on May 2, 2025. The company aims to maintain its listing on Nasdaq while adjusting its share capital and par value accordingly.
Read more →SLGL▲ +14.6%on this news· ran to +46% by day 3
Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.
Sol-Gel Technologies has entered a product purchase agreement with Mayne Pharma for the U.S. rights to EPSOLAY and TWYNEO, securing $16 million to extend its cash runway. This agreement follows the termination of a prior license with Galderma. Sol-Gel is focusing on advancing its SGT-610 program, which aims to be the first preventative treatment for basal cell carcinomas in Gorlin syndrome patients. The Phase-III trial for SGT-610 is progressing well, with expectations for timely recruitment and results.
Read more →SLGLSol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement
Sol-Gel Technologies has been granted a 180-day extension by Nasdaq to regain compliance with its minimum bid price requirement. The extension allows the company until May 19, 2025, to meet the necessary criteria. Sol-Gel plans to consider a reverse stock split if needed to achieve compliance. The company has also successfully transferred its listing to the Nasdaq Capital Market.
Read more →SLGLSol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Sol-Gel Technologies, Ltd. reported its third quarter 2024 financial results, indicating a net loss of $0.4 million. The company announced the appointment of Mori Arkin as interim CEO, effective January 1, 2025. Sol-Gel is currently conducting a Phase 3 clinical trial of SGT-610 for Gorlin syndrome and has received notable licensing agreements to strengthen its financial position. The company's Ordinary Shares will transfer to the Nasdaq Capital Market as part of compliance measures.
Read more →SLGLSol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
Sol-Gel Technologies, Ltd. reported strong financial results for Q2 2024, including a net income of $1.9 million, showcasing a significant improvement from a net loss of $6 million in the previous year. The company extended its cash runway into the first quarter of 2026, driven by cost-cutting measures and recent agreements. Key developments include the ongoing Phase 3 clinical trial for SGT-610 aimed at treating Gorlin syndrome, with top-line results expected in Q2 2026, and successful licensing agreements for TWYNEO and EPSOLAY targeting international markets. Additionally, the company announced a management realignment to optimize leadership and direction moving forward.
Read more →SLGL▼ -32.9%on this news
Sol-Gel Announces the Signing of Six Exclusive License Agreements to Commercialize TWYNEO and EPSOLAY in Europe and South Africa
Sol-Gel Technologies, Ltd. has signed six exclusive license agreements with multiple partners for the commercialization of its dermatological products, TWYNEO and EPSOLAY, in numerous European countries and South Africa. This move is expected to enhance its market presence and generate up to low 7-digit USD payments in upfront and milestone revenues. CEO Alon Seri-Levy emphasized the new agreements as a testament to Sol-Gel's innovative capacity and expressed optimism for additional partnerships in the future. However, the company acknowledges challenges such as potential delays in regulatory submissions and the significant competition in the dermatology market.
Read more →SLGL▼ -8.1%on this news
Sol-Gel Technologies Announces Management Realignment
Sol-Gel Technologies, Ltd. announced a management realignment, including the planned departure of CEO Dr. Alon Seri-Levy effective December 31, 2024, contingent on shareholder approval. Mr. Eyal Ben-Or, previously the Director of Finance, has been appointed as the new Chief Financial Officer. Dr. Seri-Levy will provide consulting services for one year post-departure. The changes come as Sol-Gel continues its clinical trials for SGT-610, a dermatological treatment for Gorlin syndrome, along with its existing product portfolio.
Read more →SLGLSol-Gel Announces Receipt of Nasdaq Minimum Price Notice
Sol-Gel Technologies, Ltd. received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement due to its shares trading below $1 for 33 consecutive days. The company has until November 18, 2024, to regain compliance by ensuring the share price meets the requirement for at least ten consecutive trading days. While the notice does not immediately affect its listing, Sol-Gel is actively assessing strategies to resolve this issue and maintain its Nasdaq status. The company continues its efforts in dermatology, including ongoing clinical trials for its product candidates.
Read more →SLGL▼ -6%on this news
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Sol-Gel Technologies, Ltd. reported its financial results for Q1 2024 and highlighted key corporate developments. The company is progressing with its Phase 3 clinical trial for SGT-610, aimed at treating Gorlin Syndrome, and has entered into an agreement with Beimei Pharma to commercialize TWYNEO in multiple markets. Despite a small revenue increase compared to the prior year, Sol-Gel reported a net loss of $6.3 million for the quarter, although this reflects improvement from the previous year. The company's cash resources are expected to sustain operations into the second half of 2025.
Read more →SLGL▲ +5.6%on this newsshared move
Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
Sol-Gel Technologies has announced an asset purchase agreement with China's Beimei Pharma to commercialize TWYNEO for acne treatment across several territories including mainland China and Taiwan. Under the agreement, Beimei gains exclusive commercialization rights, while Sol-Gel will receive an upfront payment along with potential royalty earnings. Both companies highlight the unmet clinical need for effective acne treatments in the Asian market, particularly for adolescents. This agreement is expected to pave the way for further commercialization of Sol-Gel's dermatology products.
Read more →SLGLSol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve Cream
Sol-Gel Technologies announced that its collaboration partner, Padagis, has submitted a first-to-file ANDA to the FDA for Roflumilast Cream, a generic equivalent to Zoryve Cream for treating plaque psoriasis. This submission, if approved, could allow Padagis to secure 180 days of market exclusivity and share profits with Sol-Gel. Despite the positive outlook, a patent infringement lawsuit has been initiated by Arcutis Biotherapeutics, creating potential legal hurdles for the ANDA's approval. The market for Zoryve Cream was valued at approximately $95 million recently, with further potential growth expected.
Read more →SLGLSol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments
Sol-Gel Technologies reported its full-year 2023 financial results, noting significant milestones in its clinical pipeline. The company is conducting a Phase 3 trial of SGT-610 for Gorlin syndrome, which aims to prevent basal cell carcinomas. Financially, Sol-Gel reported a decrease in revenue and an increased net loss for the year, yet maintains a cash runway into mid-2025. The potential market for SGT-610 could exceed $300 million if approved, positioning Sol-Gel for future growth amid ongoing challenges.
Read more →SLGLSol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study
Sol-Gel Technologies has initiated patient screening for its Phase 3 study of SGT-610, a topical treatment for preventing new basal cell carcinoma lesions in patients with Gorlin syndrome. This therapeutic candidate has received both Orphan Drug and Breakthrough Therapy designations from the U.S. FDA and is anticipated to address an unmet medical need. A virtual event will be held on December 6th to discuss the treatment landscape and the patient experience. If successful, SGT-610 could realize significant market potential, estimated over $300 million.
Read more →SLGLSol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610
Sol-Gel Technologies Ltd will host a virtual key opinion leader (KOL) event on December 6, 2023, to discuss Gorlin syndrome and the company's SGT-610 Phase 3 trial. The event will feature experts discussing the disease burden associated with Gorlin syndrome and the therapeutic potential of SGT-610, a hedgehog inhibitor. SGT-610 has received Orphan Drug and Breakthrough Designation from the FDA, highlighting its potential as a treatment for patients suffering from this rare genetic disorder. Attendees will have the opportunity to ask questions after the presentation.
Read more →SLGLSol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Sol-Gel Technologies reported its third quarter 2023 financial results, highlighting the progress of its Orphan Drug candidate SGT-610 for Gorlin syndrome, with plans to initiate Phase 3 testing by the end of 2023. The company maintains a healthy cash runway through the second half of 2025, supported by cost-saving measures. Additionally, recent prescription data reflects a positive trend for its approved dermatology products, TWYNEO and EPSOLAY. Despite a net loss reported for the quarter, the firm continues to focus on advancing its pipeline and securing partnerships for its marketed products.
Read more →SLGLSol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference, scheduled for September 11-13, 2023. The virtual presentation will be led by CEO Alon Seri-Levy and will be available on-demand starting at 7:00 AM EDT on September 11. The company is known for its approved dermatology products, EPSOLAY and TWYNEO, as well as for its innovative pipeline candidates aimed at treating severe skin conditions.
Read more →SLGLSol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Sol-Gel Technologies reported its Q2 2023 financial results, highlighting a partnership with Searchlight Pharma expected to provide up to $11 million in payments. The company is advancing its orphan drug candidate SGT-610 for Gorlin syndrome into Phase 3 trials later this year, following a clinical setback from a competitor. Despite positive growth in the prescribing of their products TWYNEO and EPSOLAY, Sol-Gel faces challenges with potential market saturation and reported a net loss of $6 million in the quarter.
Read more →SLGLSol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO and EPSOLAY in Canada
Sol-Gel Technologies and Searchlight Pharma have entered into exclusive licensing agreements to commercialize two dermatology products, TWYNEO and EPSOLAY, in Canada. Sol-Gel will receive up to $11 million in upfront payments along with royalties from net sales over a fifteen-year term. The agreement aims to enhance Sol-Gel's commercial presence in North America. Both products, already launched in the U.S., target acne vulgaris and rosacea, respectively, and are expected to contribute significantly to Searchlight's dermatology portfolio.
Read more →SLGLSol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update
Sol-Gel Technologies reported its financial results for Q1 2023, highlighting positive trends for its dermatology products TWYNEO and EPSOLAY with high prescriber bases. The company is preparing to initiate Phase 3 trials for its orphan drug candidate SGT-610, which shows potential in treating Gorlin syndrome. Additionally, a Phase 1 study for SGT-210 demonstrated good safety profiles, supporting its advancement. Despite an increased net loss compared to the previous year, Sol-Gel maintains a strong financial position with ample cash reserves.
Read more →SLGLSol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
Sol-Gel Technologies, a dermatology company, announced its participation in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on March 30, 2023. This event will feature a live company presentation and offer virtual one-on-one meetings with management. Sol-Gel is known for its FDA-approved products for acne and rosacea, alongside a promising pipeline including Orphan Drug candidates. The event aims to increase awareness and engagement with stakeholders.
Read more →SLGLSol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments
Sol-Gel Technologies reported its financial results for the year ending December 31, 2022, highlighting a significant acquisition of SGT-610, a potential treatment for Gorlin syndrome. The company also noted a growing base of prescribers for its existing products, TWYNEO and EPSOLAY. Despite a net loss of $14.9 million in 2022, Sol-Gel has extended its cash runway to support upcoming trials through the latter half of 2025. The company is focused on the development of effective therapies for rare diseases where there are currently no approved treatments.
Read more →SLGLSol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings
Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) has announced a concurrent offering of registered direct and private placements with expected gross proceeds of about $22.8 million. The company will issue a total of 2,560,000 ordinary shares priced at $5.00 each and unregistered warrants for the same number of shares. Additionally, an affiliate of the chairman will purchase 2 million shares and corresponding warrants within the private placement framework. Proceeds are earmarked for the acquisition of SGT-610, aimed at treating Gorlin syndrome, as well as for R&D activities and general corporate purposes.
Read more →SLGLSol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million
Sol-Gel Technologies, Ltd. announced the acquisition of patidegib, an investigational compound for the treatment of Gorlin syndrome, which could be the first therapy of its kind if approved. The upcoming Phase 3 study, modified from an earlier study, is set to begin in the second half of 2023, with results anticipated by the end of 2025. With both Breakthrough and Orphan Drug Designations from the FDA, patidegib offers a significant opportunity for Sol-Gel, potentially generating over $300 million in annual net sales. However, the success relies on the outcomes of the new Phase 3 study, which aims to address deficiencies from previous trials.
Read more →SLGLSol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Growth trends for TWYNEO and EPSOLAY continue to improve, demonstrating robust uptake by prescribers Sol-Gel’s cash runway expected to extend through the end of the first quarter of 2024 NESS ZIONA, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: S
Read more →SLGLSol-Gel Technologies Appoints Michael Glezin Vice President, Business Development
NESS ZIONA, Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today t
Read more →SLGL▼ -6.6%on this news
Sol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Prescription volumes to date indicate strong uptake, similar to successful dermatology launches Sol-Gel receives $3.5 million milestone payment from commercial partner Galderma Holding SA (“Galderma”) for FDA approval of EPSOLAY Sol-Gel’s cash runway expected to extend through
Read more →SLGLSol-Gel Technologies to Participate in the 2022 Jefferies Global Healthcare Conference
NESS ZIONA, Israel, June 01, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, today announced t
Read more →SLGLSol-Gel Technologies to Present in Upcoming H.C. Wainwright Global Investment Conference
NESS ZIONA, Israel, May 17, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, today announced th
Read more →SLGL▲ +6%on this newsshared move
Sol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate Update
FDA approval for EPSOLAY® (benzoyl peroxide, cream, 5%) represents Sol-Gel’s second approved product within less than a year; EPSOLAY is patent protected until 2040 Partner Galderma to launch two products in the U.S. this quarter: TWYNEO launched in the U.S. market in April for
Read more →SLGL▼ -7.6%on this news
Sol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY
EPSOLAY (benzoyl peroxide, cream, 5%) utilizes Sol-Gel’s proprietary microencapsulation technology for the treatment of inflammatory lesions of rosacea and is patent protected until 2040 Galderma set to commercialize EPSOLAY in the U.S. under exclusive license NESS ZIONA, Israe
Read more →SLGL▲ +9.9%on this news
Sol-Gel Technologies Announces the Commercial Availability of TWYNEO
TWYNEO is the first-ever tretinoin and benzoyl peroxide combination to treat facial acne Sol-Gel’s U.S. commercialization partner, Galderma, launched TWYNEO® in the U.S. at the Annual Meeting of the American Academy of Dermatology, March 25-29, 2022 in Boston, MA. TWYNEO is now
Read more →SLGLSol-Gel Technologies Reports Full Year 2021 Financial Results and Corporate Developments
Galderma launched TWYNEO® at the Annual Meetings of the American Academy of Dermatology, March 25-29, 2022 in Boston, MA. TWYNEO will be commercially available in Spring 2022. 2021 revenue of $31.3 million Sol-Gel to receive $21.5 million over 24 months in exchange for the tran
Read more →SLGLSol-Gel Technologies Announces U.S. Commercial Partner Galderma to Promote TWYNEO at the American Academy of Dermatology Annual Meeting to be Held March 25-29 in Boston, MA
NESS ZIONA, Israel, March 25, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that its U.
Read more →SLGLSol-Gel Technologies to Participate in Upcoming LifeSci Partners Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthcare Conference
NESS ZIONA, Israel, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announc
Read more →SLGLSol-Gel Technologies Announces Positive Update Related to FDA Review Status of EPSOLAY
FDA informs Sol-Gel that it intends to conduct a pre-approval inspection of the production site for EPSOLAY during the week of February 14th, 2022 NESS ZIONA, Israel, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on id
Read more →SLGLSol-Gel Technologies Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments
Sol-Gel attains a profitable quarter, reporting total revenues of $8.8 million, net income of $1.3 million and EPS of $0.06 Recently obtained FDA approval of TWYNEO® triggers a $3.5 million milestone payment from Galderma, and, together with the $4.0 million down payment from Ga
Read more →SLGLSol-Gel Technologies to Present Live at Jefferies London Healthcare Conference
NESS ZIONA, Israel, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Com
Read more →SLGLSol-Gel Technologies Announces Sale of Generic Dermatology Portfolio to Partner Padagis for $21 Million
- Sol-Gel to receive $21 million over 24 months in exchange for the transfer of its rights to two marketed generic drugs and eight unapproved generic programs - Sol-Gel to retain two generic programs encompassing four high-value generic drug candidates - Sol-Gel’s cash runwa
Read more →SLGL▼ -6.1%on this news
Sol-Gel Technologies to Present at Upcoming Cantor Virtual Global Healthcare Conference
NESS ZIONA, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Co
Read more →SLGLSol-Gel Technologies to Present at Upcoming H.C. Wainwright Global Investment Conference
NESS ZIONA, Israel, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Co
Read more →SLGL▼ -5.7%on this news
Sol-Gel Technologies Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments
Recently obtained FDA approval of TWYNEO® triggers milestone payment from Galderma Exclusive license agreements with Galderma for U.S. commercialization of EPSOLAY® and TWYNEO Sol-Gel advancing its early-stage pipeline in plaque psoriasis, palmoplantar keratoderma and other hig
Read more →SLGLSol-Gel Technologies Announces FDA Approval of TWYNEO
TWYNEO®, a once-daily cream treatment for acne vulgaris, is the first FDA-approved fixed-dose combination of tretinoin and benzoyl peroxide TWYNEO utilizes Sol-Gel’s proprietary microencapsulation technology and is patent protected until 2038 Under a previously announced licens
Read more →SLGLSol-Gel Technologies to Report Second Quarter 2021 Financial Results on August 4th, 2021
NESS ZIONA, Israel, July 20, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report s
Read more →SLGLSol-Gel Announces Pipeline Update and Future Development Plans
Sol-Gel investigational SGT-510 was found to be more effective than roflumilast cream, 0.3%, in a human xenograft psoriasis animal model Sol-Gel is developing tapinarof cream, 1%, aiming to offer product formulation innovations and increased affordability for patients compared t
Read more →SLGLSol-Gel Technologies to Present at Upcoming Jefferies Healthcare Conference and Raymond James Human Health Innovation Conference
NESS ZIONA, Israel, May 27, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, t
Read more →SLGLSol-Gel Technologies Reports First Quarter 2021 Financial Results and Corporate Update
- Sol-Gel is in advanced negotiations with a potential partner regarding the commercialization of EPSOLAY® and TWYNEO® - EPSOLAY PDUFA goal date was set for April 26, 2021. Awaiting FDA’s pre-approval inspection - TWYNEO PDUFA goal date set for August 1, 2021 NESS ZIONA, Israe
Read more →SLGLSol-Gel Technologies Provides Update on FDA Review of EPSOLAY
NESS ZIONA, Israel, April 27, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announ
Read more →SLGLSol-Gel Technologies Reports Full Year 2020 Financial Results and Corporate Update
• Epsolay® and Twyneo® PDUFA goal dates set for April 26, 2021 and August 1, 2021 respectively • Top-line generic product revenue of $8.7 million in fiscal 2020 • Signed additional generic product collaboration agreements with Perrigo, bringing the number of collaborations betw
Read more →SLGLSol-Gel Technologies to Present at Upcoming 2021 Raymond James Institutional Investors Conference and H.C. Wainwright Global Life Sciences Conference
NESS ZIONA, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today
Read more →SLGLSol-Gel Technologies to Present at Upcoming 2021 Solebury Trout Virtual Investor Conference and H.C. Wainwright BioConnect Conference
NESS ZIONA, Israel, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today
Read more →SLGLSol-Gel Technologies Announces FDA Acceptance for Filing of New Drug Application for Twyneo for the Treatment of Acne Vulgaris
- PDUFA Goal Date Set for August 1, 2021 - Potential to be the first acne treatment that contains a fixed-dose combination of benzoyl peroxide and tretinoin NESS ZIONA, Israel, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermato
Read more →SLGLSol-Gel Technologies Reports Third Quarter 2020 Financial Results and Corporate Update
Epsolay® PDUFA goal date set for April 26, 2021 Twyneo® New Drug Application submitted to the U.S. FDA Top-line generic product revenue of $2.1 million in 3Q 2020 In October 2020, signed an 11th generic product collaboration agreement with Perrigo NESS ZIONA, Israel, Nov. 12,
Read more →SLGLSol-Gel to Present at Upcoming Healthcare Investor Conferences in November 2020
NESS ZIONA, Israel, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today
Read more →SLGLSol-Gel Technologies to Report Third Quarter 2020 Financial Results on November 12, 2020
NESS ZIONA, Israel, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of
Read more →SLGLSol-Gel Technologies Announces FDA Acceptance for Filing of New Drug Application for Epsolay for the Treatment of Inflammatory Lesions of Rosacea
- PDUFA Goal Date Set for April 26, 2021 - Potential to be first FDA-approved single-agent benzoyl peroxide prescription drug product NESS ZIONA, Israel, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused o
Read more →SLGLSol-Gel to Present at Upcoming Healthcare Investor Conferences in September
NESS ZIONA, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today
Read more →SLGLSol-Gel Technologies Collaboration Partner Filed First-to-File Paragraph IV Certification for Duobrii
Patent challenge initiated by Bausch Health Companies NESS ZIONA, Israel, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug pr
Read more →SLGLSol-Gel Technologies Reports Second Quarter 2020 Financial Results and Corporate Update
New Drug Application for Epsolay® Submitted; Twyneo® New Drug Application on track for 2H 2020 Top-line generic product revenue of $1.1 million in 2Q 2020 Launch of additional generic product expected in 2Q 2021 NESS ZIONA, Israel, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Tec
Read more →SLGLSol-Gel Technologies to Report Second Quarter 2020 Financial Results on August 6, 2020
NESS ZIONA, Israel, July 29, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of
Read more →SLGLSol-Gel Technologies Partnered Generic Product Expected to Launch in the Second Quarter of 2021
NESS ZIONA, Israel, July 28, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announc
Read more →SLGLSol-Gel Technologies Announces Agreements with Perrigo Company for Three New Generic Product Candidates
NESS ZIONA, Israel, June 29, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announc
Read more →SLGLSol-Gel to Present at Virtual BMO 2020 Prescriptions for Success Healthcare Conference
NESS ZIONA, Israel, June 16, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of
Read more →SLGLSol-Gel to Present at Upcoming Healthcare Investor Conferences
NESS ZIONA, Israel, May 27, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of
Read more →SLGLSol-Gel Technologies Reports First Quarter 2020 Financial Results and Corporate Update
New Drug Applications for Epsolay® and Twyneo® remain on track for the second quarter and second half 2020, respectively Completed a $23 million underwritten public offering in February with an additional $5 million investment from Sol-Gel’s controlling shareholder in April, pro
Read more →SLGLSol-Gel Technologies to Report First Quarter 2020 Financial Results and Company Updates on May 14, 2020
NESS ZIONA, Israel, May 07, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of
Read more →SLGLSol-Gel Technologies Announces Closing of Additional $5.0 Million Investment
Investment is for ordinary shares and warrants to purchase ordinary shares at a combined price of $11 per ordinary share and accompanying warrants to purchase 0.80 of an ordinary share Investment brings total gross proceeds from the February 2020 transactions to $28 million NES
Read more →SLGLSol-Gel Technologies Reports Full Year 2019 Financial Results and Corporate Update
Top-line generic product revenue of $22.8 million in fiscal 2019 New Drug Applications for Epsolay® and Twyneo® remain on track for the second quarter and second half 2020, respectively NESS ZIONA, Israel, March 24, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: S
Read more →SLGLSol-Gel Technologies to Report Full Year 2019 Financial Results and Corporate Update
NESS ZIONA, Israel, March 19, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment o
Read more →SLGLSol-Gel to Present at the Cowen 40th Annual Health Care Conference
NESS ZIONA, Israel, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today
Read more →SLGLSol-Gel Announces Pricing of Public Offering of Ordinary Shares and Warrants to Purchase Ordinary Shares
NESS ZIONA, Israel, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of
Read more →SLGLSol-Gel Announces Positive Topline Results from Open-Label, Long-Term Safety Study of Epsolay for Treatment up to 52 Weeks
Successful topline results, strengthens Epsolay’s long-term safety and tolerability profile in the treatment of papulopustular rosacea Results pave the way for NDA submission in the second quarter of 2020 NESS ZIONNA, Israel, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologi
Read more →SLGLSol-Gel Provides Product Pipeline Updates and Anticipated Milestones for 2020
NESS ZIONA, Israel, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”) a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of
Read more →SLGLSol-Gel Announces Presentation of Data for its Topical Product Candidates for Acne and Rosacea at the 16th Annual Maui Derm for Dermatologists 2020 Meeting
NESS ZIONA, Israel, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”) today announced the presentation of results from the Company’s Phase 3 trials for its candidates Epsolay® (microencapsulated benzoyl peroxide cream, 5%) for
Read more →SLGLSol-Gel Hosts Investor Call to Discuss Positive Results from Twyneo Phase 3 Program in Acne Vulgaris
Conference call with Sol-Gel management and U.S. key opinion leader today at 8:00 a.m. Eastern time NESS ZIONA, Israel, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) will host a conference call today to discuss results from two Phase 3 clinical tria
Read more →SLGLSol-Gel Announces Initiation of SGT-210 Phase 1 Proof of Concept Study in Palmoplantar Keratoderma (PPK)
NESS ZIONA, Israel, Jan. 02, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) today announced the initiation of a Phase 1 proof of concept clinical study of SGT-210, its novel, topical, epidermal growth factor receptor inhibitor in patients with punctate palmopl
Read more →SLGLSol-Gel Announces Positive Top-Line Phase 3 Trial Results of Twyneo for the Treatment of Acne Vulgaris
All co-primary endpoints achieved in both Phase 3 clinical trials Twyneo was well-tolerated and the majority of local skin reactions, when reported, were mild and improved over time Additional data to be shared during the January 8th investor conference call and webcast NESS Z
Read more →SLGLSol-Gel Technologies Reports Third Quarter 2019 Financial Results and Corporate Update
Top-line generic product revenue of $4.7 million in the third quarter Results from TWIN Phase 3 trials in acne vulgaris remain on track for the fourth quarter of 2019 NESS ZIONA, Israel, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-sta
Read more →SLGLSol-Gel to Present on Potential of Sol-Gel Microencapsulation Technology in Rosacea at 39th Annual Fall Clinical Dermatology Conference
NESS ZIONA, Israel, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) today announced it will present research on the use of its proprietary microencapsulation technology in treating papulopustular rosacea, including Phase 3 results for Epsolay® microenc
Read more →SLGLSol-Gel Technologies Reports Second Quarter 2019 Financial Results and Corporate Update
Top-line generic product revenue of $7.8 million TWIN Phase 3 trials are fully enrolled and remain on track to report results in 4Q19 NESS ZIONA, Israel, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on
Read more →SLGLSol-Gel Announces Pricing of Public Offering of Ordinary Shares
NESS ZIONA, Israel, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment o
Read more →SLGLSol-Gel Technologies Hosting Analyst & Investor Day
Notice of allowance for U.S. patent application extends TWIN patent protection to 2038 Clinical study for SGT-210 in palmoplantar keratoderma (PPK) intended to begin in early 2020 Webcast of Analyst & Investor Day today at 8:30 a.m. ET NESS ZIONA, Israel, July 25, 2019 (GLOBE
Read more →SLGLSol-Gel Announces Positive Top-Line Results from Epsolay Phase 3 Program in Papulopustular Rosacea
All primary and secondary endpoints achieved in both Phase 3 clinical trials Rapid efficacy demonstrated, with statistical significance reached as early as Week 2 compared with vehicle Favorable safety and tolerability profile, similar to vehicle Conference call and webcast to
Read more →SLGLSol-Gel Technologies to Host Analyst & Investor Day on July 25, 2019
NESS ZIONA, Israel, June 17, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of
Read more →SLGLSol-Gel Technologies Announces Seventh Agreement for Generic Product Candidates with Perrigo
NESS ZIONA, Israel, May 28, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of
Read more →SLGLSol-Gel to Present at Upcoming Healthcare Investor Conferences in June
NESS ZIONA, Israel, May 23, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of
Read more →SLGLSol-Gel Technologies Reports First Quarter 2019 Financial Results and Corporate Update
Top-line results from Phase III Epsolay® and TWIN trials remain on track; mid-2019 and 4Q19, respectfully Reports top-line generic product revenues of $6.3 million NESS ZIONA, Israel, May 22, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “
Read more →SLGLSol-Gel Technologies Announces Participation in Upcoming Investor Conference
NESS ZIONA, Israel, April 18, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of
Read more →SLGLSol-Gel Technologies Announces 50% Enrollment in Pivotal Phase III TWIN Program for the Treatment of Acne Vulgaris
Patient enrollment of the pivotal Phase III TWIN clinical trials is on schedule Top-line results expected in the fourth quarter of 2019 NESS ZIONA, Israel, April 15, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage
Read more →SLGLSol-Gel Technologies Reports Full Year 2018 Financial Results and Provides Corporate Update
Company met all milestones in 2018 and this year expects to report Phase III top-line results for Epsolay® and TWIN, potentially best-in-class papulopustular rosacea and acne vulgaris topical medications Recent approval of Perrigo's generic acyclovir cream, 5%, has already provi
Read more →SLGLSol-Gel Technologies Announces FDA Approval for Perrigo’s Generic Acyclovir Cream, 5%
NESS ZIONA, Israel, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (Sol-Gel or the Company), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin
Read more →SLGLSol-Gel Technologies Appoints John Vieira as U.S. Head of Commercialization
NESS ZIONA, Israel, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of
Read more →SLGLSol-Gel Technologies Initiates Pivotal Phase III Clinical Program of TWIN for the Treatment of Acne Vulgaris
First subject dosed in pivotal Phase III program evaluating TWIN in subjects with moderate-to-severe acne vulgaris Two Phase III trials expected to enroll a total of approximately 840 subjects Top-line data anticipated by the end of 2019 NESS ZIONA, Israel, Dec. 17, 2018 (GLOB
Read more →SLGLSol-Gel Technologies Announces Sixth Agreement for a Generic Product Candidate with Perrigo
NESS ZIONA, Israel, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of
Read more →SLGLSol-Gel Technologies Reports Third Quarter 2018 Financial Results
NESS ZIONA, Israel, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of
Read more →SLGLSol-Gel Technologies Announces an Additional Collaborative Agreement for a Generic Product Candidate with Perrigo
NESS ZIONA, Israel, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of
Read more →SLGLSol-Gel Technologies Announces 50% Enrollment in Pivotal Phase III Epsolay Program for the Treatment of Papulopustular Rosacea
Patient enrollment of the pivotal Phase III Epsolay clinical trials is on schedule Top-line results expected in 2019 NESS ZIONA, Israel, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology compan
Read more →SLGLSol-Gel Technologies Names Jonathan B. Siegel to the Board of Directors
NESS ZIONA, Israel, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of
Read more →SLGLSol-Gel Technologies Provides Program Update for TWIN for the Treatment of Acne Vulgaris
Announces Positive End-of-Phase II Meeting with the FDA Receives Special Protocol Assessment (SPA) Agreement from FDA Company expects to commence the TWIN Phase III clinical trials in the fourth quarter of 2018 with top-line data expected in 2019 NESS ZIONA, Israel, Sept. 04,
Read more →SLGLSol-Gel Technologies Announces Collaborative Agreement for Generic Product with Perrigo
NESS ZIONA, Israel, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of
Read more →SLGLSol-Gel Technologies Reports Second Quarter 2018 Financial Results
NESS ZIONA, Israel, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of
Read more →SLGLSol-Gel Technologies Initiates Pivotal Phase III Clinical Program for Papulopustular Rosacea
First subject dosed in pivotal Phase III program evaluating Epsolay® in subjects with papulopustular rosacea Two Phase III trials expected to enroll a total of 700 subjects Top-line data expected to be reported in 2019 NESS ZIONA, Israel, June 18, 2018 (GLOBE NEWSWIRE) -- Sol-
Read more →SLGLSol-Gel Technologies Announces Participation in Upcoming Investor Conferences
NESS ZIONA, Israel, May 29, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ:SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of sk
Read more →SLGLSol-Gel Technologies Reports First Quarter 2018 Financial Results
NESS ZIONA, Israel, May 15, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ:SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of sk
Read more →SLGLSol-Gel Technologies Ltd. Availability of Its Annual Report on Form 20-F Through Its Website
NESS ZIONA, Israel, March 26, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ:SLGL), a clinical-stage dermatology company, announced today that it filed its Annual Report for 2017 on Form 20-F, containing audited financial statements for the year ended December 31, 201
Read more →SLGLSol-Gel Technologies Reports Fourth Quarter and Full Year 2017 Financial Results
NESS ZIONA, Israel, March 26, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ:SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of
Read more →SLGLSol-Gel’s Phase 2 Data on TWIN and VERED to be Presented at the 2018 American Academy of Dermatology Annual Meeting
NESS ZIONA, Israel, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (“Sol-Gel”) (NASDAQ:SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, tod
Read more →SLGLSol-Gel Technologies Ltd. AMENDED AND RESTATED ARTICLES OF ASSOCIATION EFFECTIVE AS OF: JANUARY 31 , 2018 TABLE OF CONTENTS INTERPRETATION 1 NAME OF THE COMPANY 2 OBJECTIVES 2 PUBLIC COMPANY 2 LIMITED LIABILITY 3 CAPITAL
AND RESTATED ARTICLES OF ASSOCIATION AS OF: JANUARY 31, 2018 INTERPRETATION 1 NAME OF THE COMPANY 2 OBJECTIVES 2 PUBLIC COMPANY 2 LIMITED LIABILITY 3 CAPITAL, SHARES AND RIGHTS 3 REGISTERED HOLDER 4 TRANSFER OF SHARES 4 TRANSMISSION OF SHARES 5 CALLS ON SHARES 5 ALTERATIONS OF
Read more →SLGLSol-Gel Technologies Ltd. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
NESS ZIONA, Israel, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (“Sol-Gel”) (NASDAQ:SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, tod
Read more →SLGLSol-Gel Technologies Ltd. Announces Pricing of Initial Public Offering
NESS ZIONA, Israel, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (“Sol-Gel”) (NASDAQ:SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, tod
Read more →SLGLSol-Gel Announces Positive Phase 2 Clinical Trial Results for TWIN in Patients with Acne Vulgaris
TWIN Achieved Primary and Secondary Efficacy Endpoints with Statistical Significance and a Favorable Tolerability Profile Subject to End of Phase 2 Meeting to be Scheduled with the FDA, Commencement of Phase 3 Program Planned for 2018 Further Validation of Sol-Gel’s Silica-bas
Read more →Competitive Position
How SLGL ranks across every disease it competes inCompetitive Position is a premium feature
See how SLGL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial